Twitter Beğeni Hilesi

Update on the EV-103 study. Thanks to all the of participants and their families. ecancer.org/en/video/9738-…

Great start to the BCAN 2023 meeting!

Amazing results of EV-302 trial yesterday, significant improvements in OS, PFS, ORR and CR rates. Over half of control arm pts got PD1 therapies, including 30% use of maintenance avelumab, making this an apt really world comparison. #ESMO2023 #bladdercancer #enfortumab

Listening to a great talk reviewing what’s new in urothelial cancer by my good friend and colleague Dr Petros Grivas Petros Grivas #curioscience #bladdercancer

Latest updates in RCC with my good friend Dr Benjamin Maughan Benjamin L Maughan . Exciting data with belzutifan and new TKI / IO combos!#kidneycancer Curio Science GU Cancer Research Program @HuntsmanCancer

Discussing LITESPARK-005 trial. Some patients getting good responses (22.5% PR, 3.5% CR rates) and durable PFS with #belzutifan in late line, TKI-pretreated pts. Benjamin L Maughan Curio Science #RCC

Concluding another amazing Prostate Cancer Foundation PCF Science retreat with lots of great science and celebration of 2023 class of Young Investigators UCSF Helen Diller Family Comprehensive Cancer Ctr UCSFUrology @HemoncUcsf Xiaolin Zhu Balaji Alan H Bryce Pedro C Barata, MD MSc FACP Rohit Bose Charles Ryan Andrea Miyahira Howard Soule

So excited to to finally see our trial of combining check point inhibitors (pembrolizumab) with a single dose of 177Lu-PSMA-617 finally get published in The Lancet Oncology. Great team work UCSF Helen Diller Family Comprehensive Cancer Ctr. Amazing PSA50 (56%) and duration of response with a single dose of RLT!

Great start to Uromigos Live meeting. Lots to discuss in frontline mUC space. All star pane here! #UromigosLive 2023

Great Rising Stars session at #UromigosLive.

Awesome end to #UromigosLive with my good friend Vadim Vadim Koshkin MD . Nashville is gorgeous

Great talk today by Kala Sridhar KSridhar at #ESMOAsia2023 on the current landscape in bladder cancer. So many new developments in such a short time!

Long awaited combination of Sacituzumab plus Immunotherapy in the JCO. Congrats to Dr Grivas Petros Grivas all the authors. pubmed.ncbi.nlm.nih.gov/38261969/

Awesome #BCANTT24 this year. Great representation from #UCSF!

First tweet!